Clinical Trial Detail

NCT ID NCT03049189
Title Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients (COMPETE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors ITM Solucin GmbH
Indications

gastrointestinal neuroendocrine tumor

pancreatic endocrine carcinoma

Therapies

177Lu-edotreotide

Everolimus

Age Groups: senior adult

No variant requirements are available.